TY  - JOUR
A1  - Hofgaard, Peter O.
A1  - Jodal, Henriette C.
A1  - Bommert, Kurt
A1  - Huard, Bertrand
A1  - Caers, Jo
A1  - Carlsen, Harald
A1  - Schwarzer, Rolf
A1  - Schünemann, Nicole
A1  - Jundt, Franziska
A1  - Lindeberg, Mona M.
A1  - Bogen, Bjarne
T1  - A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease
JF  - PLoS One
N2  - Multiple myeloma (MM) is a lethal human cancer characterized by a clonal expansion of malignant plasma cells in bone marrow. Mouse models of human MM are technically challenging and do not always recapitulate human disease. Therefore, new mouse models for MM are needed. Mineral-oil induced plasmacytomas (MOPC) develop in the peritoneal cavity of oil-injected BALB/c mice. However, MOPC typically grow extramedullary and are considered poor models of human MM. Here we describe an in vivo-selected MOPC315 variant, called MOPC315.BM, which can be maintained in vitro. When injected i.v. into BALB/c mice, MOPC315.BM cells exhibit tropism for bone marrow. As few as 10\(^4\) MOPC315.BM cells injected i.v. induced paraplegia, a sign of spinal cord compression, in all mice within 3-4 weeks. MOPC315.BM cells were stably transfected with either firefly luciferase (MOPC315.BM.Luc) or DsRed (MOPC315.BM.DsRed) for studies using noninvasive imaging. MOPC315.BM.Luc cells were detected in the tibiofemoral region already 1 hour after i.v. injection. Bone foci developed progressively, and as of day 5, MM cells were detected in multiple sites in the axial skeleton. Additionally, the spleen (a hematopoietic organ in the mouse) was invariably affected. Luminescent signals correlated with serum myeloma protein concentration, allowing for easy tracking of tumor load with noninvasive imaging. Affected mice developed osteolytic lesions. The MOPC315.BM model employs a common strain of immunocompetent mice (BALB/c) and replicates many characteristics of human MM. The model should be suitable for studies of bone marrow tropism, development of osteolytic lesions, drug testing, and immunotherapy in MM.
KW  - resistance
KW  - CD4(+) T-cells
KW  - tumor specific antigen
KW  - plasma cells
KW  - B cell
KW  - C57BL/KALWRIJ mouse
KW  - bone disease
KW  - scid mice
KW  - idiotype
KW  - differentiation
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131117
VL  - 7
IS  - 12
ER  - 
TY  - JOUR
A1  - Ludwig, Heinz
A1  - Delforge, Michel
A1  - Facon, Thierry
A1  - Einsele, Hermann
A1  - Gay, Francesca
A1  - Moreau, Philippe
A1  - Avet-Loiseau, Hervé
A1  - Boccadoro, Mario
A1  - Hajek, Roman
A1  - Mohty, Mohamad
A1  - Cavo, Michele
A1  - Dimopoulos, Meletios A
A1  - San-Miguel, Jesús F
A1  - Terpos, Evangelos
A1  - Zweegman, Sonja
A1  - Garderet, Laurent
A1  - Mateos, María-Victoria
A1  - Cook, Gordon
A1  - Leleu, Xavier
A1  - Goldschmidt, Hartmut
A1  - Jackson, Graham
A1  - Kaiser, Martin
A1  - Weisel, Katja
A1  - van de Donk, Niels W. C. J.
A1  - Waage, Anders
A1  - Beksac, Meral
A1  - Mellqvist, Ulf H.
A1  - Engelhardt, Monika
A1  - Caers, Jo
A1  - Driessen, Christoph
A1  - Bladé, Joan
A1  - Sonneveld, Pieter
T1  - Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
JF  - Leukemia
N2  - During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.
KW  - disease prevention
KW  - myeloma
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-237338
VL  - 32
ER  -